A BILL 
To amend the Federal Food, Drug, and Cosmetic Act with 
respect to the accelerated approval of a product for a 
serious or life-threatening disease or condition, and for 
other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Accelerating Access 
4
for Patients Act of 2022’’. 
5
18:21 Mar 14, 2022
H6996
2 
•HR 6996 IH
SEC. 2. ACCELERATED APPROVAL. 
1
(a) IN GENERAL.—Subsection (c) of section 506 of 
2
the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
3
356) is amended to read as follows: 
4
‘‘(c) ACCELERATED APPROVAL OF A DRUG FOR A SE-
5
RIOUS OR LIFE-THREATENING DISEASE OR CONDITION, 
6
INCLUDING A FAST TRACK PRODUCT.— 
7
‘‘(1) IN GENERAL.— 
8
‘‘(A) ACCELERATED APPROVAL.—The Sec-
9
retary may approve an application for approval 
10
of a product for a serious or life-threatening 
11
disease or condition, including a fast track 
12
product, under section 505(c) of this Act or sec-
13
tion 351(a) of the Public Health Service Act 
14
upon a determination— 
15
‘‘(i) that the product has an effect on 
16
a surrogate endpoint that is reasonably 
17
likely to predict clinical benefit, or on a 
18
clinical endpoint that can be measured ear-
19
lier than irreversible morbidity or mor-
20
tality, that is reasonably likely to predict 
21
an effect on irreversible morbidity or mor-
22
tality or other clinical benefit, taking into 
23
account the severity, rarity, or prevalence 
24
of the disease or condition and the avail-
25
ability or lack of alternative treatments; or 
26
18:21 Mar 14, 2022
H6996
3 
•HR 6996 IH
‘‘(ii) of the safety and effectiveness of 
1
the product based on the known benefit- 
2
risk profile of such product in the intended 
3
population, taking into account the sever-
4
ity, rarity, or prevalence of the disease or 
5
condition and the availability or lack of al-
6
ternative treatments. 
7
‘‘(B) COMPREHENSIVE
CLINICAL
DEVEL-
8
OPMENT PLAN.—The Secretary shall establish 
9
procedures by which a sponsor of a product 
10
seeking approval described in subparagraph (A) 
11
may meet with appropriate officials of the Food 
12
and Drug Administration to develop a plan to 
13
provide clarity and certainty for the sponsor re-
14
garding the applicability of the requirements of 
15
this subsection. Such a plan shall include— 
16
‘‘(i) a determination as to whether the 
17
product subject to such approval is in-
18
tended to treat an unmet medical need; 
19
‘‘(ii) an agreement on the surrogate 
20
or intermediate clinical endpoint to be as-
21
sessed, if applicable; 
22
‘‘(iii) an agreement on the design of 
23
the studies to be conducted to support the 
24
approval; 
25
18:21 Mar 14, 2022
H6996
4 
•HR 6996 IH
‘‘(iv) a plan for a postapproval study 
1
to satisfy paragraph (2)(A), if required, in-
2
cluding a plan for reaching agreement on 
3
the design of any such study; 
4
‘‘(v) a plan for reaching agreement on 
5
the types of developmental milestones to be 
6
met; and 
7
‘‘(vi) a strategy for the inclusion of di-
8
verse populations. 
9
‘‘(C) EVIDENCE.—The evidence to support 
10
that an endpoint is reasonably likely to predict 
11
clinical benefit under subparagraph (A)(i) may 
12
include 
epidemiological, 
pathophysiological, 
13
therapeutic, pharmacologic, or other evidence 
14
developed using biomarkers, for example, or 
15
other scientific methods or tools. 
16
‘‘(D) REFERENCES.—In this section, ap-
17
proval described in subparagraph (A) is re-
18
ferred to as ‘accelerated approval’. 
19
‘‘(2) LIMITATION.—Approval of a product 
20
under this subsection may be subject to 1 or both 
21
of the following requirements: 
22
‘‘(A) That the sponsor conduct appropriate 
23
postapproval studies (which may include clinical 
24
evidence, patient registries, or other sources of 
25
18:21 Mar 14, 2022
H6996
5 
•HR 6996 IH
real world evidence) to verify and describe the 
1
predicted effect on irreversible morbidity or 
2
mortality or other clinical benefit. 
3
‘‘(B) That the sponsor submit copies of all 
4
promotional materials related to the product 
5
during the preapproval review period and, fol-
6
lowing approval and for such period thereafter 
7
as the Secretary determines to be appropriate, 
8
at least 30 days prior to dissemination of the 
9
materials. 
10
‘‘(3) GUIDANCE.—The Secretary shall issue— 
11
‘‘(A) guidance describing criteria, proc-
12
esses, and other general considerations for dem-
13
onstrating the safety and effectiveness of drugs 
14
submitted for approval described in paragraph 
15
(1)(A)(ii); and 
16
‘‘(B) guidance on the use of novel clinical 
17
trial designs that may be used to conduct ap-
18
propriate postapproval studies as may be re-
19
quired under paragraph (2)(A). 
20
‘‘(4) APPROVAL
OF
STUDY
PROTOCOL.—Not 
21
later than 60 calendar days after the submission by 
22
the sponsor of a product of a proposed protocol for 
23
a postapproval study required under paragraph 
24
(2)(A), the Secretary shall— 
25
18:21 Mar 14, 2022
H6996
6 
•HR 6996 IH
‘‘(A) approve the protocol; or 
1
‘‘(B) specify changes to the protocol that 
2
would enable such approval. 
3
‘‘(5) 
EXPEDITED
WITHDRAWAL
OF
AP-
4
PROVAL.—The Secretary may withdraw approval of 
5
a product approved under accelerated approval using 
6
expedited procedures (as prescribed by the Secretary 
7
in regulations which shall include an opportunity for 
8
an informal hearing) if— 
9
‘‘(A) the sponsor fails to conduct any re-
10
quired postapproval study of the product with 
11
due diligence; 
12
‘‘(B) a study required to verify and de-
13
scribe the predicted effect on irreversible mor-
14
bidity or mortality or other clinical benefit of 
15
the product fails to verify and describe such ef-
16
fect or benefit; 
17
‘‘(C) other evidence demonstrates that the 
18
product is not safe or effective under the condi-
19
tions of use; or 
20
‘‘(D) the sponsor disseminates false or 
21
misleading promotional materials with respect 
22
to the product. 
23
‘‘(6) REPORTING.—Not later than 180 days 
24
after the date of enactment of the Accelerating Ac-
25
18:21 Mar 14, 2022
H6996
7 
•HR 6996 IH
cess for Patients Act of 2022, and annually there-
1
after, the Secretary shall submit to the Committee 
2
on Energy and Commerce of the House of Rep-
3
resentatives and the Committee on Health, Edu-
4
cation, Labor, and Pensions of the Senate a report 
5
describing— 
6
‘‘(A) the circumstances and number of ap-
7
plications submitted for approval described in 
8
paragraph (1)(A) for which real world evidence 
9
was deemed appropriate to support or fulfill 
10
postapproval studies required under this sub-
11
section; and 
12
‘‘(B) the circumstances and number of ap-
13
plications submitted for approval described in 
14
paragraph (1)(A) for which real world evidence 
15
was submitted for such postapproval studies.’’. 
16
(b) INITIAL GUIDANCE.—The Secretary of Health 
17
and Human Services, acting through the Commissioner of 
18
Food and Drugs— 
19
(1) shall issue draft guidance pursuant to sec-
20
tion 506(c)(3) of the Federal Food, Drug, and Cos-
21
metic Act, as amended by subsection (a), not later 
22
than 18 months after the date of enactment of this 
23
Act; 
24
18:21 Mar 14, 2022
H6996
8 
•HR 6996 IH
(2) shall promulgate final guidance pursuant to 
1
such section 506(c)(3) not later than 18 months 
2
after the close of the public comment period on such 
3
draft guidance; and 
4
(3) may approve products as described in sec-
5
tion 506(c)(1)(A) of the Federal Food, Drug, and 
6
Cosmetic Act, as amended by subsection (a), prior to 
7
issuing initial draft or final guidance under this sub-
8
section. 
9
Æ 
18:21 Mar 14, 2022
H6996
